RA Capital Management is a Boston-based investment firm that provides multi-stage capital to public and private healthcare, life sciences, and planetary health companies. The firm supports management teams from early seed rounds to later financings, seeking to drive value through scientific and clinical data, product development, and commercialization. It complements capital with value-added services such as board representation, executive recruitment, and market intelligence through its TechAtlas research platform. The company also operates Raven, a healthcare incubator that helps entrepreneurs build biomedical ventures, and emphasizes a collaborative, data-driven approach and long-term relationships. RA Capital pursues social responsibility by advocating for affordable medicines and industry advancement, and it invests across U.S. and European opportunities, including early-stage and growth-stage rounds.

OrbiMed is a global healthcare investment firm based in New York that funds companies across the healthcare spectrum. It uses multiple strategies, including private equity for startups and growth-stage companies, private credit and royalty financing for intellectual property and medical diagnostics, and public equity investments. The firm targets biopharmaceuticals, biotechnology, medical devices, diagnostics, digital health, and health IT, supporting development of new therapies and health technologies. OrbiMed operates internationally with offices in major markets and manages substantial assets across public and private investments, staffed by a team of professionals to identify opportunities and support portfolio companies.

Eli Lilly and Company is a global biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing medicines across neuroscience, cardiometabolic, cancer, and immunology. The company operates manufacturing and distribution facilities in the United States, Puerto Rico, and multiple countries, with products sold in about 135 markets worldwide. Through ongoing research and development, Lilly aims to deliver therapies that improve patient outcomes and access to medicines. Its portfolio includes treatments such as Mounjaro and Jardiance for cardiometabolic diseases, Verzenio and Jaypirca for cancer, Trulicity and Humalog for diabetes, and Taltz and Olumiant for immunology, among others. Lilly emphasizes safety and quality in manufacturing and supports patients through educational and support initiatives, reflecting a long history of pharmaceutical leadership and a commitment to advancing personalized medicine.

Norwest is a venture capital and growth equity investment firm that focuses on venture and growth-stage companies. Since its inception, it has invested in more than 600 companies and partnered with over 140 active companies across its venture and growth equity portfolio. The firm backs early to late-stage companies across sectors with a focus on consumer, enterprise, and healthcare, and it provides a deep network of connections, operating experience, and a broad range of services to help CEOs and founders scale their businesses.

Founded in 1985, The Invus Group is a global private equity firm that partners with entrepreneurs, founders and management teams across the company lifecycle. Blending a family-office approach with multi-strategy investing, it supports transformative growth in sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education and medical devices. The firm pursues long-term value creation through strategic insight, capital and execution, investing in companies from early stages to mature businesses and providing both lead investments and co-investments in private transactions worldwide. It maintains a global footprint with offices in New York, London, Paris and Hong Kong and has a flexible structure designed to align incentives with partners over time.

Vivo Capital is a global healthcare investment firm founded in 1996 and based in Palo Alto, California, with offices in Asia. It operates a multi-fund platform spanning growth equity, private equity including buyouts, venture capital, and public equity, and invests broadly in biotechnology, pharmaceuticals, medical devices, and healthcare services across major markets. The firm pursues opportunities worldwide, supporting companies at various development stages with a team of physicians, scientists, entrepreneurs, operating executives, and industry experts who contribute deep sector insight. It manages approximately $5.8 billion in assets under management.

Novo Nordisk is a global healthcare company focused on discovering, developing, and delivering medicines for serious chronic diseases, with a core emphasis on diabetes care. The organization produces and distributes insulin and other therapies aimed at treating diabetes and related conditions, while investing heavily in scientific research and biopharmaceutical innovation. Through partnerships and sustained commitments to accessibility, Novo Nordisk seeks to improve patient outcomes and support health systems worldwide. The company operates across many markets, supported by its production of insulin pens and a broad portfolio addressing obesity, rare blood and endocrine disorders, and other chronic diseases. It pursues long-term social responsibility and sustainability as integral to its business model.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong and Singapore. It backs early and growth-stage technology, consumer and healthcare companies, applying deep industry knowledge and hands-on support to help portfolio companies scale. The firm manages US-dollar and RMB funds and maintains a global footprint, including a dedicated US arm, Qiming Venture Partners USA, to pursue cross-border opportunities in healthcare, therapeutics and digital health. Since inception, it has invested in more than 530 companies and achieved more than 200 exits via IPOs, M&A or other means, with over 70 portfolio companies reaching unicorn or super unicorn status. Qiming emphasizes long-term partnerships with entrepreneurs, aligning resources and networks to drive innovation and societal progress across its portfolio.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, that invests in biotechnology and healthcare companies across the United States. The firm supports biotech ventures by providing capital and strategic guidance to help advance innovative therapies and discoveries. It operates as a registered investment adviser, offering investment advisory services to entrepreneurs and venture teams as they work to bring new biotech solutions to market.

Venrock is a Palo Alto-based venture capital firm with a history dating to 1969 as the venture capital arm of the Rockefeller family. It concentrates on technology and healthcare, providing seed and early-stage funding to entrepreneurs pursuing disruptive ideas. Its portfolio has included Apple, Intel, Illumina, Gilead Sciences, Nest, DoubleClick, Endeca, SlideShare, Athenahealth, and Tudou, among others, illustrating its experience across software, hardware, life sciences, and digital health. Venrock operates with a global perspective and maintains offices in Palo Alto, California and New York City, supporting startups through long-term partnerships and active involvement in company building.

New Enterprise Associates is a venture capital firm founded in 1977 and based in Menlo Park, California, with a global investment reach. It provides capital and operational support to early, growth, and later-stage companies across a wide range of industries, including software, consumer technology, healthcare technology, life sciences, energy technology, infrastructure, and AI-enabled services. NEA collaborates with founders to address technical challenges, guide product development, and expand markets, leveraging its domain expertise to help portfolio companies scale from seed stages through IPO. The firm invests across the United States, Asia, and other regions, often supporting companies from early stages to scale, and has a long track record that includes numerous IPOs and acquisitions. NEA emphasizes a hands-on partnership approach and seeks opportunities across sectors that enable transformational businesses through technology and data-driven innovation.

Redmile Group is a San Francisco-based investment firm focused on healthcare, including life sciences and oncology; it engages in venture, growth and crossover investing and operates an office in New York.

Morningside Group is a venture capital firm founded in 1986, originally established as a family office for the Chan family, and is based in the greater Boston area. The firm makes venture investments in companies with novel science and technology, pursuing a long-term, patient approach to company-building and emphasizing ethical practices. Its investment focus spans life sciences, digital health, artificial intelligence, materials science, and information technology. In addition to its investment activities, Morningside supports charitable initiatives in education, research, and healthcare, with partnerships including the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

Deep Track Capital is a Greenwich, Connecticut-based venture capital investment firm that concentrates on life sciences and biotechnology. It partners with management teams of innovative public and pre-IPO biotech companies, offering capital, strategic guidance, and access to its industry network. The firm aims to lead transactions, build large syndicates, and participate in rounds led by other investors, leveraging expertise in healthcare finance, biotech investing, and drug development to support portfolio companies through development and growth.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven startups, especially in life sciences, biotechnology, healthcare, and related technologies. It backs companies co-founded by scientists and entrepreneurs and supports commercialization of innovations developed at academic research institutions and national laboratories. The firm takes a long-term, hands-on approach, leveraging its network to assist portfolio companies from inception to market realization and to build transformative enterprises. ARCH has raised ten venture funds totaling over $3 billion and has invested in more than 150 companies worldwide, reflecting a focus on strategic value creation and governance.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco, with offices in Canada, the United States, and Europe. The firm invests across the healthcare sector at all stages, with emphasis on the discovery and development of novel therapeutics, including pharmaceuticals, biotechnology, medical devices, and life sciences. Versant combines investment, operating, and scientific expertise to support portfolio companies through strategic guidance and hands-on involvement in company building. The firm manages substantial capital, enabling a hands-on approach to helping entrepreneurs build durable companies addressing high unmet medical needs.

Founded in 2020, the European Innovation Council is a Brussels-based venture capital initiative that supports top innovators, entrepreneurs, small companies, and researchers with bright ideas. It co-invests with private investors in early-stage startups, prioritizes deep technology ventures, and pursues ESG-positive impacts to accelerate commercialization and scale-up.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. It provides seed through growth capital to life science and technology companies developing breakthrough therapies, diagnostics, research tools, agrifoodtech, agtech, digital health, and related platforms. Backed by the parent company’s industry experience and scientific advisory network, the firm leverages long-standing relationships and domain expertise to support early to growth-stage ventures aiming to translate scientific advances into practical healthcare and technology solutions.

Deerfield Management is a New York-based healthcare investment firm established in 1994. It manages investments across public and private markets in healthcare products and services, including therapeutics, medical devices, diagnostics, digital health, and health services. The firm combines capital deployment with research and strategic intelligence through Deerfield Intelligence and supports innovation via Deerfield Discovery and Development (3DC) and a philanthropic foundation focused on education, healthcare access, and health outcomes.

Logos Capital is a biotechnology-focused investment firm headquartered in San Francisco. The company applies disciplined, data-driven diligence across medical, scientific, and clinical disciplines to identify transformative therapies in healthcare. By combining in-house analytics with rigorous clinical evaluation, Logos Capital seeks to back life-changing therapeutics with strong value propositions. The firm emphasizes rigorous opportunity identification, thorough clinical trial underwriting, and proactive risk management, leveraging advanced analytics to predict trial outcomes and support informed investment decisions. Its approach aims to deliver compelling returns while contributing to patient outcomes by supporting companies with transformative technologies.

TCG Crossover is a science-driven venture capital firm focused on healthcare and biotechnology. It invests in biotechnology and pharmaceutical companies across the United States and Europe, supporting the development of medicines through a network of scientific advisors and resources that help navigate clinical and regulatory challenges. The firm has teams in Palo Alto and New York City and pursues long-term partnerships with entrepreneurs to translate cutting-edge science into meaningful patient outcomes.

Forbion is a global venture capital firm based in Naarden, Netherlands, focused on biotech innovations and sustainable solutions to improve human and planetary health. It invests across human health, planetary health and the bioeconomy, spanning pre-clinical, early clinical and growth stages, and combines company building with venture capital while integrating ESG principles. With two decades of experience and about €5 billion under management across 11 funds, Forbion backs companies in Europe and North America across life sciences, pharmaceuticals and biotechnology sectors.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

Boxer Capital is a biotechnology investment firm that invests in private and public companies across the full drug development lifecycle, from early discovery to late-stage clinical and commercial programs. Based in the United States, it operates as part of the Tavistock Group and concentrates on biotechnology, life sciences, and precision and specialized medicine. The firm emphasizes disciplined, science-driven analysis and a multidisciplinary approach, with bottom-up idea generation supported by experienced scientists, aiming to advance innovative targets and therapies that improve patient care. It pursues opportunistic venture investments across private and public markets.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. Founded in 2012, the company operates as an investment adviser and venture investor, seeking to identify and support innovative therapeutic solutions with the potential to improve patient outcomes. It provides investment services to pooled vehicles and participates in biotech investments across private and public markets, reflecting a commitment to advancing medical research.

Pfizer is a global pharmaceutical company that develops, manufactures, and sells medicines and vaccines across a broad range of therapeutic areas. It aims to provide safe, effective, and affordable health care solutions and services that support wellness, prevention, and treatment. The company maintains a substantial portfolio of prescription medicines and vaccines and pursues a robust pipeline of new products and technologies intended to address major diseases, including cancer and neurodegenerative conditions. Pfizer conducts business worldwide, with a significant share of international sales and a broad geographic footprint. Founded in 1849 and headquartered in the United States, Pfizer focuses on research and development, manufacturing scale, and strategic collaborations to improve patient outcomes and expand access to therapies.

SOSV is a global venture capital firm founded in 1995 and headquartered in New Jersey. The firm focuses on seed-to-growth investments in deep tech sectors, including biotech and life sciences, hardware and robotics, and cross-border software with emphasis on markets in Asia. It supports startups from early stages with investment capital as well as resources such as laboratories, collaborative spaces, and expert mentorship to accelerate product development and market traction. SOSV operates purpose-built programs to help portfolio companies raise follow-on funding, scale operations, and reach customers, often through structured matchmaking and access to a global network of investors. With a broad portfolio spanning hundreds of companies worldwide, SOSV aims to foster innovation, build vibrant entrepreneurial ecosystems, and contribute to sustainable technological advancement.

Omega Funds is a Boston-based venture capital firm founded in 2004 that focuses on early-stage investments in healthcare and biotech. It backs companies across biotechnology, pharmaceuticals, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, with activity in North America and Western Europe. The firm manages multiple funds and operates as a registered investment adviser, leveraging its network to support entrepreneurs and advance innovations in medicine and related technologies.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focusing on life sciences. It finances start-ups, early-stage companies, corporate spin-offs, and occasional turnarounds in biopharmaceuticals, biotech, medical devices, and related areas. The firm often acts as a lead or cornerstone investor and is frequently the first institutional backer in Series A rounds, maintaining an active role including board seats from formation through exit. It pursues global opportunities and emphasizes thorough due diligence on portfolio companies, including management and intellectual property considerations. The firm was established in 1972.

Hercules Capital is a specialty finance company that provides venture debt and senior secured loans to venture capital-backed companies across technology and life sciences. It focuses on structured debt and growth capital, offering financing options such as working capital facilities, equipment loans, and other debt instruments to high-growth, expansion-stage firms, complementing equity rounds and allowing companies to extend runways while preserving ownership. The firm primarily invests in United States-based companies across software, hardware, semiconductors, healthcare, and related sectors, including energy technology and information services. Exits are pursued through initial public offerings, private sales, mergers or acquisitions, or other liquidity events. Known for sector expertise and a broad capital base, it emphasizes flexible, customized financing solutions that align with a portfolio company's milestones and capital structure needs.

Atlas Venture is a Cambridge-based venture capital firm with a 30-year history of building life sciences companies. Founded in 1980, it focuses on early-stage opportunities in biotechnology, biopharmaceuticals, diagnostics, medical devices, and related life sciences, as well as technology sectors. The firm uses a seed-led venture creation approach and often leads initial rounds, providing strategic guidance and board representation to portfolio companies. Its portfolio has included the development of more than 25 medicines and the launch of eight startups through its incubator program, and it has facilitated 43 IPOs and 39 M&A exits. Atlas operates with a global reach across the United States and Europe, supporting life science entrepreneurs in translating scientific advances into therapies and commercial opportunities.

HBM Healthcare Investments is a Swiss investment firm founded in 2001 that focuses on delivering access to a globally diversified portfolio of healthcare companies. Headquartered in Switzerland, the firm targets opportunities across human medicine, biotechnology, medical technology and diagnostics, investing in both private and public companies with established or near-market products. It emphasizes active portfolio management and provides strategic guidance to portfolio companies to support value creation. By leveraging demographic trends and medical innovation, the firm seeks attractive returns while maintaining a diversified asset mix that includes private holdings, public equities and funds. The company is noted for an attractive dividend policy with a yield around five percent.

SR One is the corporate venture capital arm of GlaxoSmithKline. It invests globally in emerging life science companies pursuing innovative science with potential to significantly improve medical care. The firm adopts a back-and-build approach, supporting founders and entrepreneurs to translate scientific discoveries into new medicines. With a transatlantic presence on the West Coast of the United States and London, SR One provides geographic reach, expertise, and timely business support to its portfolio. Since 1985, SR One has invested about 800 million across more than 180 companies.

Merck is a global healthcare company that discovers, develops, manufactures, and markets medicines, vaccines, biologic therapies, and animal health products. Its research focuses on oncology, vaccines, infectious diseases, and immunology, with efforts to translate scientific breakthroughs into therapies that address unmet medical needs. The company maintains a broad immuno-oncology platform anchored by Keytruda and a sizeable vaccine business including Gardasil, aimed at preventing human papillomavirus–related diseases. Merck operates globally, with a substantial portion of sales from the United States, and pursues sustainability and responsible business practices. Through its diverse portfolio and worldwide presence, Merck strives to advance health outcomes for people and animals through innovations across medicines, vaccines, and animal health products.

F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts, with a long history of investing in healthcare and technology companies. It backs early-stage and growth companies across life sciences, including therapeutics, medtech, and healthtech, and technology sectors such as enterprise software, fintech, frontier tech, and crypto, with a global reach across the Americas, Europe, and Asia. The firm manages about 4.8 billion in capital and relies on a multidisciplinary team of scientists, engineers, physicians, operators, and investors to help portfolio companies accelerate scalable growth. It also provides advisory support, leveraging deep sector expertise and operational experience to guide portfolio companies toward meaningful breakthroughs.

Mission BioCapital is a life sciences venture capital firm established in 2009 and based in Cambridge, Massachusetts, that funds early-stage biotechnology companies and supports them through clinical development. The firm emphasizes mentorship and practical assistance, offering entrepreneurs access to laboratory space, incubator networks, and programs designed to accelerate progress and secure follow-on funding. Its approach combines capital with hands-on guidance across discovery, development, and commercialization, leveraging a history of supporting dozens of startups. Through a broad ecosystem in the United States and Europe, Mission BioCapital aims to translate scientific discoveries into tangible solutions by pairing funding with operational support, expert advice in areas such as drug discovery, legal, and accounting, and strategic mentorship to help portfolio companies reach milestones and attract subsequent investment.

Takeda is a global biopharmaceutical company focused on developing and delivering medicines across oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. It researches, develops, manufactures, markets, and sells pharmaceutical drugs and vaccines to improve patient health worldwide. The company maintains a diversified geographic footprint, with substantial activity in the United States, Japan, Europe and Canada, and operates a broad portfolio of therapies designed to address unmet medical needs. Takeda emphasizes research and development, pursuing innovation in gastrointestinal and inflammatory diseases, oncology, and neuroscience, while upholding commitments to patient outcomes, ethical practices, and sustainability. It is Japan’s largest pharmaceutical company by several metrics.

Kurma Partners is a Paris-based European investment firm that funds innovation in healthcare and biotechnology. It invests across development stages, from early research to growth, with a focus on therapeutics, diagnostics, and HealthTech/MedTech. The firm works with leading research centers and hospitals, maintains a broad European footprint with a strong presence in France, and pursues responsible investing aligned with ESG principles. Its portfolio emphasizes sustainable impact and collaboration with researchers and entrepreneurs to advance medical solutions.

Frazier Healthcare Partners is a Seattle-based healthcare-focused investment firm founded in 1991 that operates as a private equity and growth capital investor. It pursues two main strategies: growth buyouts of healthcare services and pharmaceutical businesses, and life sciences investments in biopharmaceuticals. The firm backs profitable US middle-market companies across the healthcare spectrum, including devices and supplies, pharmaceuticals and biotechnology, healthcare services, manufacturing, life sciences, oncology and wellness, with investments in the United States, Canada and Europe. It partners with industry executives to scale portfolio companies, often acting as lead investor and taking board seats to guide strategic growth. Frazier manages multiple funds and operates as a registered investment adviser.

Ally Bridge Group is a private investment group focusing on healthcare and life sciences. It pursues venture, growth equity, and buyout opportunities in both private and public markets. The firm targets innovative life science companies spanning pharmaceuticals, medical devices, diagnostics, and healthcare IT, with emphasis on transformative therapies and disruptive platforms. It operates globally, with offices in Hong Kong and the United States, and was founded in 2013. The firm supports portfolio companies through strategic guidance and an extensive network to bridge innovations to global markets.

Commodore Capital is a New York-based venture capital firm founded in 2019 that concentrates on early-stage investments in biopharmaceuticals, backing innovations across the major biopharmaceutical innovation cycle. The firm operates as a registered investment adviser.

Nextech Invest is a Zurich-based investment firm dedicated to early-stage healthcare and life sciences companies, with a particular focus on oncology and precision medicine. It identifies and invests in emerging biotechnology ventures, providing support through scientific validation and value creation across the company’s lifecycle. The firm pursues opportunities globally, funding companies across continents and enabling technologies that advance therapies, diagnostics, and medical technologies. It operates independently in the life sciences and related fields and aims to build a portfolio of promising ventures with potential to improve cancer care and related healthcare outcomes.

Canaan Partners is a global venture capital firm founded in 1987 and based in Menlo Park, California, with East Coast offices in Westport, Connecticut and an international presence in Israel and India. It focuses on early-stage investments in technology and healthcare companies, targeting sectors such as fintech, enterprise software and cloud, marketplaces, frontier tech, biopharma, digital health and medtech. The firm emphasizes close collaboration with founders, providing strategic guidance and hands-on support to help portfolio companies grow and scale. Over its history it has funded hundreds of startups across information technology and life sciences, building a diversified portfolio and a track record of supporting transformative ideas from inception to growth.

Casdin Capital is an investment firm focused on life sciences and healthcare. Founded in 2012 by Eli Casdin and based in New York, it seeks opportunities across the life sciences spectrum, including biotechnology, digital health, oncology, agtech, and healthcare services. The firm pursues early- to late-stage private investments and, at times, long-short equity strategies, leveraging data-driven insights, molecular information, and precision medicine to identify transformative opportunities. It emphasizes patient capital, disciplined investing, and strong collaborations to support companies advancing diagnostics, therapeutics, and sustainable solutions. By capturing and processing data to unlock breakthroughs, Casdin Capital backs teams with the potential to transform modern medicine.

VenBio Partners is a California-based venture capital firm focused on life sciences and healthcare, investing across the drug discovery spectrum from early to late stages in the United States. The firm tends to lead its investments, builds syndicates, and positions portfolio companies to meet potential acquisition partners from the outset. It concentrates on preparing companies in areas such as intellectual property, chemistry, manufacturing and controls (CMC), and clinical trial design and regulatory considerations to maximize impact. Supported by an experienced team, VenBio aims to form lasting relationships with leaders in the field and help portfolio companies advance meaningful therapies.

MPM Capital is a healthcare investment firm that finances biotechnology, life sciences, and medical technologies with the aim of translating science into clinical outcomes. The firm backs companies across stages from seed through late venture and growth, including oncology, medical devices, specialty pharma, and diagnostics, with investments typically spanning global opportunities in the United States, Europe, and Asia. It often serves as a lead investor and may take interim operating roles to support portfolio companies, leveraging a three-decade track record in building biotechnology and healthcare companies.

5AM Ventures is a San Francisco-based venture capital firm that provides seed- and early-stage funding to companies in the life sciences, healthcare, and related technology sectors. Its portfolio focuses on biopharmaceuticals, medical technology, and life science instruments, with investments across the United States. Founded in 2002 by John Diekman and Andrew Schwab, the firm operates from its San Francisco base and maintains an office in Boston. 5AM Ventures partners with scientists and entrepreneurs to advance breakthrough therapies and diagnostic tools, supporting companies through early development and growth.

High-Tech Gründerfonds is a Germany-based venture capital firm established in 2005 that funds early-stage technology startups in Germany. Based in Bonn with an office in Berlin, it supports companies across software, information technology, digital and industrial tech, life sciences, chemistry, IoT, energy, and related fields by providing initial capital and subsequent funding, complemented by active guidance from investment managers. The firm typically acts as a lead investor and cooperates with other investors to help portfolio companies advance from concept to market, with a focus on startups that have begun commercial operations. By combining financing with hands-on support, HTGF aims to help high-potential founders develop their technology, validate products, and scale within the German market.

Aisling Capital is a New York-based private investment firm that specializes in healthcare and life sciences, making mid-market and growth-oriented investments in companies across the United States and Western Europe. Founded in 2000, the firm manages over $1.8 billion and provides capital along with strategic guidance to support the development and commercialization of innovative therapeutics, diagnostics, services, and technologies addressing unmet medical needs.

European Investment Fund is the EU's financing arm for small and medium-sized enterprises and mid-caps, providing financial instruments to improve access to affordable financing for businesses across their lifecycle, with a focus on innovation, growth, competitiveness, social impact and sustainability. The EIF leverages its capital base to foster public-private partnerships and allocates guarantees and equity funding to catalyze lending and investment for startups and small businesses throughout Europe, including EU member states, candidate countries and EFTA countries. It collaborates with partners to close funding gaps and support entrepreneurship and economic resilience.